GLP1R and Hepatic steatosis: SGLT2i and GLP1-R agonists are antidiabetic agents gaining an emerging role in managing MASLD, with an increasing body of evidence from both experimental and clinical studies in reducing hepatic steatosis and lowering associated cardiovascular risk.